Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (September 2005)

34 slides from Anesiva's merger presentation, Sep 26, 2005

  1. Slide 1: Corgentech and AlgoRx Announce Merger Agreement

    Corgentech and AlgoRx Announce Merger Agreement September 26, 2005

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv

  4. Slide 4: Creating a Late-Stage Company

    CREATING LATE-STAGE COMPANY Multiple late-stage product development programs focused on significant clinical problems – Pain management – Inflammatory diseases Brings together development and commercial expertise in critical areas – Marketing, commercialization, regulatory affairs and clinical trial

  5. Slide 5: Agenda

    AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense

  6. Slide 6: Terms of Merger Agreement

    TERMS OF MERGER AGREEMENT Stock Transaction – As of the date of closing of the merger agreement, Corgentech would issue sufficient shares such that AlgoRx shareholders would receive, in a tax-free exchange, 62% of the combined company and Corgentech shareholders would own 38% of the combined company

  7. Slide 7: Agenda

    AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense

  8. Slide 8: Product Pipeline

    PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX 3268 Pre-procedural analgesia ALGRX 4975 Post-surgical pain Morton’s neuroma Tendonitis NF-KB Decoy Atopic dermatitis (eczema) ALGRX 1207 Cutaneous neuropathic pain

  9. Slide 9: ALGRX 3268 - Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication – Reduction of pain associated with needlesticks for venipunctures and intravenous line placements Phase 3 trial underway – Clinical data expected in second half of 2005 Key desirable product attributes – Sterile, pre-filled, needle-free disposable del

  10. Slide 10: ALGRX 3268: Reduction in Pain from Venipuncture

    ALGRX 3268 Reduction in Pain from Venipuncture after Administration EMLA Package Insert for EMLA VAS, mm 10 0 -10 -20 -30 Time after administration, minutes ALGRX 3268 VAS, mm 10 0 -10 -20 -30 Time after administration, minutes ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a

  11. Slide 11: ALGRX 3268 Development

    ALGRX 3268 DEVELOPMENT Protocol Age Group Phase Total Patients Primary Endpoint Status Primary Endpoint Antecubital Fossa Adults 1 272 Safety and Efficacy Achieved Primary Endpoint Back of Hand Adults 1 183 Safety and Efficacy Achieved Evaluate Circulating Primary Endpoint Pharmacokinetics Adults 1

  12. Slide 12: ALGRX 4975 - VR1 Anesthetic

    ALGRX 4975 – VR1 ANESTHETIC Activates the VR1 channel; expressed by pain receptor C-fibers Capsaicin Overview Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does n

  13. Slide 13: ALGRX 4975 Development

    ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery 2 40 Time to Rescue Medication Primary Endpoint Achieved Bunion Removal Surgery 2 182 Magnitude of Pain Relief Primary Endpoint Achieved Hernia Repair 2 48 Magnitude and Duration of

  14. Slide 14: Eczema: Large Unmet Need

    ECZEMA: LARGE UNMET NEED Unmet medical need – Existing therapies are not satisfactory (steroids and calcineurin inhibitors) – Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on on calcineurin inhibitors Strong preclinical data with

  15. Slide 15: NF-kB Decoy for Eczema

    NF-KB DECOY FOR ECZEMA Two Phase 1/2 trials underway Clinical data expected in 1Q/06 Adults with mild-moderate eczema Endpoints – Safety, tolerability and PK – Multiple endpoints to assess preliminary efficacy Physician and patient assessments of target area (signs and symptoms) US Trial (75 patient

  16. Slide 16: ALGRX 1207

    ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: – Neuropathic pain – Dermatological surgery – Surgical incisions

  17. Slide 17: ALGRX 1207

    ALGRX 1207 New local anesthetic allowing rapid and complete topical anesthesia without exotic delivery Percent complete anesthesia 100 80 60 40 20 0 -120 -110 -100 -90 Time, minutes Percent complete anesthesia 100 80 60 40 20 0 -120 -60 0 60 120 180 240 300 360 420 Time, minutes Lidocaine ALGRX 1207

  18. Slide 18: Agenda

    AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense

  19. Slide 19: Prevalence of Pain in Seven Major Countries

    PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES PATIENT NUMBERS (in thousands) Prevalence of post-operative pain 75,068 Prevalence of back pain 208,996 Prevalence of HIV and AIDS pain 847 Prevalence of diabetic neuropathy pain 13,243 Prevalence of osteoarthritic pain 46,610 Above indications are all tar

  20. Slide 20: 3268: Topical Local Anesthesia Market Dynamics

    3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put in hos

  21. Slide 21: 3268: Needlestick/Venipuncture Marketplace in the U.S.

    3268: NEEDLESTICK/VENIPUNCTURE MARKETPLACE IN THE U.S. 42M Pediatric in-hospital 315M Adult in-hospital 40M Hemodialysis visits 54K Pediatric physician offices 11K Outpatient care centers1 1.3K Blood donation centers1 At home self-administration market 1. 2001 US census

  22. Slide 22: 3268: TLAs in Pediatric Hospital Settings

    3268: TLAs IN PEDIATRIC HOSPITAL SETTINGS Relevant Pediatric Procedures Surgery/ IV Insertions 12% Spinal Tap/ LPs 12% Chemotherapy 1% Blood Draws 48% IV Insertions 27% 18 million procedures* Treated Relevant Procedures Spinal Tap/ LPs 11% Chemotherapy 3% Surgery/ IV Insertions 19% IV Insertions 35%

  23. Slide 23: 3268: Current Clinical Practice of TLAs in Hospital Setting

    3268: CURRENT CLINICAL PRACTICE OF TLAs IN HOSPITAL SETTING Many hospitals offer TLA agents as an option to reduce needlestick pain – Existence of established protocols for TLA use is mixed – Nurses rather than physicians usually decision maker Some ERs apply TLAs, however use is often impractical d

  24. Slide 24: 3268: Phased Marketing Approach

    3268: PHASED MARKETING APPROACH Physican Offices, Labs, Blood donation centers Hemodialysis Centers In-hospital Adult (ER) In-hospital Pediatric 18M

  25. Slide 25: 4975: Post-Operative Pain Market

    4975: POST-OPERATIVE PAIN MARKET US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively – 50% indicate lack of adequate pain control – Patients’ post-surgical pain experiences between 1993 and 1999 have not improved – Europe also under treat

  26. Slide 26: 4975: Potential Targets - High Volume Surgical Procedures

    4975: POTENTIAL TARGETS—HIGH VOLUME SURGICAL PROCEDURES Procedure Volume Caesarean Section 1,163,893 Hysterectomy (all) 1,042,715 Episiotomy 417,699 Arthroplasty (knee) 399,139 Hip Replacement, 343,554 total/partial CABG 316,471 Colorectal resection 280,969

  27. Slide 27: Current Post-Op Pain Medications vs. ALGRX 4975

    CURRENT POST-OP PAIN MEDICATIONS VS. ALGRX 4975 Epidurals – Use declining significantly due to contra-indication in combination use with anticoagulants Opioids – Nausea, vomiting, respiratory depression and constipation – Sedation may limit the ability of the patient to ambulate and prolong time to

  28. Slide 28: NF-kB Decoy: Eczema Market

    NF-KB DECOY: ECZEMA MARKET Eczema market is comprised of mild, moderate and severe patient segments within the pediatric and adult patient populations Patient Population Segmented by Mild, Moderate and Severe (US, EU, Japan) Severe 10% 15.6M 5.2M 31.1M Moderate 30% Mild 60% Sources: 1. International

  29. Slide 29: NF-kB Decoy: Retail Rx Sales (U.S.)

    NF-KB DECOY: RETAIL Rx SALES (U.S.) Total Dollars (millions) $900 $800 $700 $600 $500 $400 $300 $200 $100 $0 1999 2000 2001 2002 2003 2004 Corticosteroids Protopic Elidel Source: IMS Health, 2004

  30. Slide 30: 1207: Target Market

    1207: TARGET MARKET Deep, rapid penetration of the skin Long duration of action Addresses neuropathic pain market Non-exotic delivery Lidoderm® (Endo Pharmaceuticals) Postherpetic Neuralgia Indication ($ in millions) $45 $107 $215 $300 $400 2001 2002 2003 2004E 2005E (IMS) (IMS) (IMS) (Endo) (Endo)

  31. Slide 31: Agenda

    AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense

  32. Slide 32: Deal Timeline

    DEAL TIMELINE Merger requires stockholder approval – Both boards have approved the merger Merger documents to be filed in coming weeks – S-4 and related joint Proxy Statement Shareholder vote expected to occur in late 2005 / early 2006

  33. Slide 33: Agenda

    AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense

  34. Slide 34: Why This Merger Makes Sense

    WHY THIS MERGER MAKES SENSE Multiple late-stage product development programs focused on significant clinical problems – Pain management – Inflammatory diseases Brings together development and commercial expertise in critical areas – Marketing, commercialization, regulatory affairs and clinical trial

Algorx Pharmaceuticals — Merger or Acquisition (September 2005) on 6ix